Xenetic Biosciences, Inc. (XBIO): R&D Expense
$3.07M
Year ended 2025-12-31
$2.74M
Trailing 12 months to 2026-06-30
-13.7%
3-year compound annual growth
+12.1%
5-year compound annual growth
-1.1%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.07M | -6.8% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $3.29M | -5.9% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $3.49M | -26.7% | 2025-03-18, From 2023-01-01 |
| 2022-12-31 | $4.77M | +50.8% | 2024-03-21, From 2022-01-01 |
| 2021-12-31 | $3.16M | +82.7% | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | $1.73M | -64.6% | 2022-03-22, From 2020-01-01 |
| 2019-12-31 | $4.89M | +69.5% | 2021-03-16, From 2019-01-01 |
| 2018-12-31 | $2.88M | -29.0% | 2020-03-26, From 2018-01-01 |
| 2017-12-31 | $4.06M | -90.7% | 2019-03-29, From 2017-01-01 |
| 2016-12-31 | $43.74M | n/m | 2018-03-30, From 2016-01-01 |
| 2015-12-31 | $3.43M | -45.7% | 2017-03-31, From 2015-01-01 |
| 2014-12-31 | $6.32M | +106.6% | 2016-03-30, From 2014-01-01 |
| 2013-12-31 | $3.06M | +57.5% | 2015-07-20, From 2013-01-01 |
| 2012-12-31 | $1.94M | n/a | 2015-07-20, From 2012-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | 2025-12-31 | $3.07M | -6.8% |
| Upstream Bio, Inc. (UPB) | 2025-12-31 | $136.81M | +117.3% |
| Cartesian Therapeutics, Inc. (RNAC) | 2025-12-31 | $58.03M | +28.7% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $38.20M | -1.6% |
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | $11.80M | -12.4% |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | $18.12M | -23.6% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $21.82M | +16.1% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $280.9K | -1.1% |
| Korsana Biosciences, Inc. (KRSA) | 2025-12-31 | $959.0K | +235.3% |
Compare XBIO, UPB, RNAC, CAMP side by side · Screen every company in Pharmaceutical Preparations ↗